Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from MaxCyte ( (MXCT) ) is now available.
MaxCyte announced that John Johnston, a Non-Executive Director, exercised options for 3,000 shares of the company’s common stock and sold them at a price range of $3.995 to $4.060. This transaction was part of a pre-established trading plan and represents a small portion of Johnston’s total equity and option holdings, impacting his stake in the company but not significantly affecting MaxCyte’s overall operations or market position.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell engineering industry, focused on providing platform technologies that advance the discovery, development, and commercialization of next-generation cell therapeutics. The company supports the rapidly expanding cell therapy market through its ExPERT platform, which utilizes Flow Electroporation technology and includes a family of products such as instruments, processing assemblies, and software protocols.
YTD Price Performance: -3.55%
Average Trading Volume: 48,524
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £346.3M
See more insights into MXCT stock on TipRanks’ Stock Analysis page.
